Rethinking Childhood-Onset Hypertrophic Cardiomyopathy: A Review of Molecular Mechanisms and Unique Therapy...

Area of Science:

• Pediatric Cardiology
• Genetics
• Molecular Biology

Background:

• Childhood-onset hypertrophic cardiomyopathy (HCM) presents unique challenges in diagnosis and treatment compared to adult-onset forms.
• Current management strategies are largely extrapolated from adult guidelines, potentially leading to suboptimal care in children.
• Advances in molecular genetics reveal age-specific disease modifiers and genotype-phenotype correlations in pediatric HCM.

Purpose of the Study:

• To review the molecular basis, clinical implications, and management strategies specifically for childhood-onset HCM.
• To highlight the current gaps in evidence regarding treatment efficacy and safety in pediatric populations.
• To discuss emerging therapeutic approaches and the need for further research.

Main Methods:

• Literature review focusing on childhood-onset hypertrophic cardiomyopathy.
• Analysis of molecular genetics, clinical manifestations, and current treatment modalities.
• Exploration of novel therapeutic avenues and precision medicine frameworks.

Main Results:

• Molecular genetics has identified distinct pathogenic pathways and age-specific modifiers in childhood HCM.
• Existing treatments (pharmacologic, surgical, device-based) lack robust evidence for pediatric efficacy and safety.
• Gene-targeted therapies and precision medicine show potential but require further investigation.

Conclusions:

• There is a critical need for research to develop evidence-based, individualized treatment paradigms for childhood-onset HCM.
• Early diagnosis and personalized care are essential for improving long-term outcomes and reducing disease burden in affected children.
• Refining risk stratification and treatment strategies tailored to pediatric populations is paramount.